

Note to readers with disabilities: *EHP* strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in *EHP* articles may not conform to [508 standards](#) due to the complexity of the information being presented. If you need assistance accessing journal content, please contact ehp508@niehs.nih.gov. Our staff will work with you to assess and meet your accessibility needs within 3 working days.

Supplemental Material

Per- and Polyfluoroalkyl Substances (PFAS) and Lipid Trajectories in Women 45–56 Years of Age: The Study of Women’s Health Across the Nation

Habyeong Kang, Ning Ding, Carrie A. Karvonen-Gutierrez, Bhramar Mukherjee, Antonia M. Calafat, and Sung Kyun Park

Table of Contents

Table S1. Detection frequencies and concentrations of serum PFAS in the SWAN-MPS cohort (1999–2016, n = 1130).

Table S2. Timeline of measurements of variables used in this study.

Table S3. Constant values added to measured lipid concentrations (mg/dL) for those with the statin or non-statin medication depending on race/ethnicity (Wu et al. 2007).

Table S4. Criteria to select a best model for total cholesterol trajectories in the SWAN-MPS cohort (1999–2016, n = 1130, adding constant methods).

Table S5. Criteria to select a best model for LDL cholesterol trajectories in the SWAN-MPS cohort (1999–2016, n = 1130, adding constant methods).

Table S6. Criteria to select a best model for HDL cholesterol trajectories in the SWAN-MPS cohort (1999–2016, n = 1130, adding constant methods).

Table S7. Criteria to select a best model for triglycerides trajectories in the SWAN-MPS cohort (1999–2016, n = 1130, adding constant methods).

Table S8. Classification of study participants in the SWAN-MPS cohort (1999–2016, n = 1130) by lipids trajectories from two different methods (Adding constant and covariate methods).

Table S9. Associations of serum concentrations of total PFOS, PFDA, PFUnDA, MeFOSAA, and EtFOSAA with trajectories of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides in the SWAN-MPS cohort (1999–2016, n = 1130).

Table S10. Associations of tertiles of serum PFAS concentrations with total cholesterol trajectories in the SWAN-MPS cohort (1999–2016, n = 1130).

Table S11. Associations of tertiles of serum PFAS concentrations with LDL cholesterol trajectories in the SWAN-MPS cohort (1999–2016, n = 1130).

Table S12. Associations of tertiles of serum PFAS concentrations with HDL cholesterol trajectories in the SWAN-MPS cohort (1999–2016, n = 1130).

Table S13. Associations of tertiles of serum PFAS concentrations with triglycerides trajectories in the SWAN-MPS cohort (1999–2016, n = 1130).

Table S14. Associations of serum PFAS concentrations with trajectories of total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides when the models were not adjusted for BMI in the SWAN-MPS cohort (1999–2016, n = 1130).

Table S15. Cross-sectional association of serum PFAS concentrations (ng/mL) with blood lipid levels at baseline (mg/dL) in the SWAN-MPS cohort (1999–2016, n = 1130).

Table S16. Association of serum PFAS concentrations (ng/mL) with rate of change in blood lipid levels during follow-up (mg/dL/year) in the SWAN-MPS cohort (1999–2016, n = 1130).

Method for literature review of studies on the association of PFAS exposure with lipids

Table S17. Summary of results of selected epidemiological studies on associations between PFAS and lipids.

Figure S1. Spearman's correlations between serum PFAS concentrations in the SWAN-MPS cohort (1999–2016, n = 1130).

Figure S2. Trajectories of (A) total cholesterol, (B) LDL cholesterol, (C) HDL cholesterol, and (D) triglycerides identified by latent class growth model in the SWAN-MPS cohort (1999–2016, n = 1130). 'Covariate method' (described in the Methods of the main text) was applied to consider lipid-lowering medication effects.

Figure S3. Odds ratios (●) and their 95% confidence intervals (bar) for associations of tertiles of PFAS concentrations (versus tertile 1) or PFAS mixture (versus low concentration) with trajectories (high versus low trajectories) of (A) total cholesterol, (B) LDL cholesterol, (C) HDL cholesterol, and (D) triglycerides when the models were not adjusted for BMI in the SWAN-MPS cohort (1999–2016, n = 1130). The models were adjusted for site × race/ethnicity, age, education, menopausal status, smoking status, alcohol consumption, physical activity, and total energy intake. The numbers at the right side of the bars represent odds ratios and their 95% confidence intervals. Results with continuous PFAS concentrations can be found in supplemental Table S14.

Figure S4. Means of the standardized log-transformed serum PFAS concentrations in each cluster identified by k-means clustering in the SWAN-MPS cohort (1999–2016, n = 1130). Cluster 1 (n=291): "low" overall PFAS concentration pattern; clusters 2 (n=569): "medium" overall PFAS concentration pattern; cluster 3 (n=270): "high" overall PFAS concentration pattern.

References